Published on:
March 6, 2026
Non-invasive prenatal testing, widely known as NIPT, has become one of the most talked-about advances in antenatal care over the past decade. Offered as a simple blood test during the first trimester, it promises a window into your baby's chromosomal health — without the small but real risks associated with invasive procedures such as amniocentesis. But as reassuring as NIPT can be for many expectant parents, it is frequently misunderstood. Understanding both its capabilities and its limitations is essential before making decisions based on its results. This guide explains exactly what NIPT is, what conditions it screens for, and — crucially — what it cannot tell you.
NIPT analyses fragments of cell-free fetal DNA (cfDNA) that circulate in the pregnant person's bloodstream. During pregnancy, small fragments of DNA shed by the placenta enter the maternal bloodstream, and from around ten weeks of gestation, these fragments are present in sufficient quantities to be analysed with reasonable accuracy. A blood sample is taken from the pregnant person's arm — hence "non-invasive" — and sent to a laboratory where the genetic material is sequenced and evaluated.
The laboratory looks for chromosomal imbalances: too many or too few copies of a given chromosome. Most chromosomal conditions screened by NIPT arise from having an extra copy (trisomy) of a chromosome. The test is particularly focused on chromosomes 21, 18, and 13, which correspond to Down's syndrome, Edwards' syndrome, and Patau's syndrome respectively. Some panels also evaluate sex chromosomes, which can indicate conditions such as Turner syndrome or Klinefelter syndrome.
It is worth noting that the DNA analysed is predominantly of placental origin, not directly from the fetus itself. In rare instances, the placenta and the fetus can have different chromosomal make-ups — a phenomenon known as confined placental mosaicism — which can affect the reliability of results. This is one of several reasons why NIPT is classified as a screening tool rather than a diagnostic one.
The core conditions screened by a standard NIPT panel include:
Extended NIPT panels may also screen for microdeletions — small missing segments of chromosomes — such as DiGeorge syndrome (22q11.2 deletion). However, the evidence base for microdeletion screening is less robust, and false positive rates tend to be higher for these rarer conditions. It is important to discuss with your clinician or genetic counsellor which panel is appropriate for your circumstances before having the test performed. Our pre-NIPT counselling service can help you navigate these choices with expert, personalised guidance.
Perhaps the single most important fact about NIPT is this: it is a screening test, not a diagnostic test. This distinction matters enormously when interpreting results. As MedlinePlus Genetics explains, NIPT "will not give a definitive answer about whether or not a fetus has a genetic condition. The test can only estimate whether the risk of having certain conditions is increased or decreased."
A "high risk" or "screen positive" NIPT result does not mean your baby has a chromosomal condition — it means the probability is elevated and further investigation is warranted. Conversely, a "low risk" or "screen negative" result significantly reduces the likelihood of those specific conditions, but does not eliminate the possibility entirely. False positives (the test suggests a problem when there is none) and false negatives (the test misses a real condition) both occur, albeit relatively rarely for the main trisomies.
Factors that can influence accuracy include the fetal fraction (the proportion of cfDNA in the maternal blood that comes from the placenta), maternal weight, gestational age, and whether the pregnancy is a singleton or multiple. If the fetal fraction is too low — which occurs more commonly in early gestation or in women with a higher BMI — the laboratory may be unable to return a result at all, necessitating a repeat test or alternative approach.
Diagnostic certainty, when needed, requires invasive testing: either chorionic villus sampling (CVS), typically performed between 11 and 14 weeks, or amniocentesis, carried out from around 15 weeks. These procedures carry a small risk of pregnancy loss but provide a definitive chromosomal diagnosis. For many families, a high-risk NIPT result is the first step on a pathway that leads to one of these confirmatory tests.
Understanding the limitations of NIPT is just as important as knowing what it covers. NIPT does not screen for the majority of genetic conditions that can affect a baby. The vast landscape of inherited genetic disorders — including single-gene conditions such as cystic fibrosis, sickle cell disease, and spinal muscular atrophy — falls entirely outside the scope of standard NIPT panels.
NIPT also does not assess fetal anatomy. Structural abnormalities such as heart defects, spinal cord issues, or cleft palate are identified through ultrasound scanning, not through cfDNA analysis. This is why your 20-week anomaly scan remains an essential part of antenatal care, even if your NIPT result was reassuring. If you have concerns about structural development, a clinical geneticist can help interpret findings in the context of your full clinical picture.
Additionally, NIPT cannot detect conditions that arise from maternal genes alone, de novo mutations that emerge after conception in ways not reflected in the placental DNA, or the vast majority of chromosomal rearrangements. It is not a substitute for a comprehensive genetic work-up where that is indicated by family history or other clinical factors.
NIPT is available to all pregnant people, though it is most commonly recommended for those at higher risk of chromosomal conditions. Risk factors include advanced maternal age (generally considered 35 or over at delivery), a previous pregnancy affected by a chromosomal condition, abnormal findings on first-trimester combined screening (which includes nuchal translucency ultrasound and blood markers), or a known parental chromosomal rearrangement.
In the UK, the NHS currently offers NIPT to those identified as higher risk following the combined first-trimester screen, as described by NHS Inform. However, NIPT is also widely available privately for all pregnant people who wish to have it, typically from ten weeks of pregnancy onwards.
If you are considering NIPT, particularly if you have a personal or family history of genetic conditions, speaking to a genetic counsellor before the test is strongly advised. A counsellor can help you understand what the test can and cannot detect, how you might respond to different results, and what follow-up options would be available to you. Our dedicated genetic counselling service provides exactly this kind of personalised, sensitive support.
Most NIPT results are returned within seven to fourteen days of the blood draw. Results are typically reported as either "low risk" or "high risk" (sometimes termed "screen negative" or "screen positive") for each condition tested. Some laboratories also provide a numerical probability, such as a risk figure of 1 in 10,000 for trisomy 21.
If your result is low risk, this is generally very reassuring, though it does not constitute a guarantee. You should continue with your routine antenatal care, including your anatomy scan. If your result is high risk, try not to panic. Your healthcare provider or genetic counsellor will discuss the result with you, explain what it means statistically, and outline your options — which may include confirmatory invasive testing, further detailed ultrasound, or in some cases, referral to a fetal medicine specialist.
It is also worth knowing that results can sometimes be inconclusive — for instance, if the fetal fraction is insufficient. In such cases, the test may need to be repeated, or alternative screening strategies may be recommended. Whatever your result, you should never feel pressured to make immediate decisions; take time, seek specialist advice, and access appropriate support.
Beyond the science, NIPT carries significant emotional weight. For many parents, the test offers welcome reassurance during an already anxious time. For others, particularly those who receive high-risk results, it can be the beginning of a deeply challenging period filled with uncertainty and difficult choices. Regardless of your circumstances, emotional support is an integral part of the NIPT journey, not an optional extra.
Genetic counsellors are trained not only to explain results but also to support families emotionally and help them navigate complex decisions without directive pressure. If you are finding the experience of prenatal testing stressful — which is entirely understandable — please do reach out to a qualified professional. Our team also supports patients with common pregnancy issues, and can signpost you to appropriate resources throughout your antenatal journey.
Yes. NIPT is a blood test taken from the pregnant person's arm and poses no physical risk to the pregnancy. Unlike amniocentesis or CVS, it does not involve any procedure near the uterus or placenta. It is considered one of the safest forms of prenatal screening available.
For trisomy 21 (Down's syndrome), NIPT has a detection rate of approximately 99% with a false positive rate of less than 0.1% in many studies. However, accuracy can be affected by factors such as fetal fraction, maternal weight, and whether the pregnancy is a singleton or twin. A positive result should always be confirmed with diagnostic testing before any major decisions are made.
No. NIPT screens for a limited number of chromosomal conditions — primarily trisomies 21, 18, and 13, and some sex chromosome conditions. It does not screen for the majority of inherited genetic disorders, structural abnormalities, or most rare chromosomal rearrangements. If you have a family history of a specific inherited condition, speak to a genetic counsellor about targeted testing options.
A high-risk result is not a diagnosis. You should seek prompt follow-up with a genetic counsellor or fetal medicine specialist who can explain your result, discuss confirmatory testing options such as CVS or amniocentesis, and support you in making informed decisions. Do not rely solely on online information or make irreversible decisions based on a screening result alone.
NIPT can typically be performed from ten weeks of gestation onwards, when sufficient fetal DNA is circulating in the maternal bloodstream. Testing before this point increases the likelihood of an inconclusive result due to a low fetal fraction. Most clinics recommend testing between ten and fourteen weeks for optimal accuracy.
The information provided in this article is for educational purposes only and is based on NHS recommendations. It is not a substitute for professional medical advice. Always consult your doctor or a qualified healthcare provider for advice on medical conditions or treatments.
Our medical centre is at 36 Spital Square, E1 6DY, City of London.
